Mechanisms of pain in arthritis.
Inflammation in the joint causes peripheral sensitization (increase of sensitivity of nociceptive primary afferent neurons) and central sensitization (hyperexcitability of nociceptive neurons in the central nervous system). The processes of sensitization are thought to be the basis of arthritic pain that appears as spontaneous pain (joints at rest) and hyperalgesia (augmented pain response on noxious stimulation and pain on normally nonpainful stimulation). Sensitization also facilitates efferent neuronal processes through which the nervous system influences the inflammatory process. Peripheral sensitization is produced by the action of inflammatory mediators such as bradykinin, prostaglandins, neuropeptides, and cytokines which activate corresponding receptors in proportions of nerve fibers. In addition, the expression of receptors, for example, bradykinin and neurokinin 1 receptors, is upregulated during inflammation. The development of hyperexcitability of spinal cord neurons is produced by various transmitter/receptor systems that constitute and modulate synaptic activation of the neurons. The key transmitter is glutamate that activates N-methyl-d-aspartate (NMDA) and non-NMDA receptors on spinal cord neurons. Blockade of these receptors prevents and reduces central sensitization. Excitatory neuropeptides (substance P and calcitonin gene-related peptide) further central sensitization. Central sensitization also is facilitated by mediators that have complex actions (e.g., prostaglandin E(2)). Spinal PGE(2) binds to receptors at presynaptic endings of primary afferent neurons (thus influencing synaptic release) and to receptors on postsynaptic spinal cord neurons. The administration of PGE(2) to the spinal cord surface produces changes of responsiveness of spinal neurons similar to peripheral inflammation, and spinal indomethacin to the spinal cord attenuates development of hyperexcitability significantly.
Schaible
Hans-Georg
HG
Department of Physiology, Friedrich-Schiller University of Jena, Jena, Germany. schaible@mti-n.uni-jena.de
Ebersberger
Andrea
A
Von Banchet
Gisela Segond
GS
D000344:Afferent Pathways / Q000503:physiopathology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001168:Arthritis / Q000503:physiopathology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015232:Dinoprostone / Q000502:physiology; D004525:Efferent Pathways / Q000503:physiopathology; D005727:Ganglia, Spinal / Q000503:physiopathology; D018698:Glutamic Acid / Q000502:physiology; D006801:Humans; D006930:Hyperalgesia / Q000209:etiology / Q000503:physiopathology; D018836:Inflammation Mediators / Q000502:physiology; D015640:Ion Channel Gating; D008465:Mechanoreceptors / Q000502:physiology; D008954:Models, Biological; D009479:Neuropeptides / Q000502:physiology; D009619:Nociceptors / Q000502:physiology; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D051381:Rats; D018013:Receptors, Neuropeptide / Q000502:physiology; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology; D018078:Receptors, Prostaglandin E / Q000502:physiology; D013116:Spinal Cord / Q000503:physiopathology
D018712:Analgesics, Non-Narcotic; D016861:Cyclooxygenase Inhibitors; D018836:Inflammation Mediators; D009479:Neuropeptides; D018013:Receptors, Neuropeptide; D017981:Receptors, Neurotransmitter; D018078:Receptors, Prostaglandin E; D018698:Glutamic Acid; D015232:Dinoprostone